An interventional study of N,N-Dimethyltryptamine and Placebo in Major Depressive Disorder and Psychedelic Experiences, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Depressive Disorder, Major with a site in Switzerland — 7 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Switzerland.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, this one is the 10th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, and was the 26th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →7 of the 30 studies in Depressive Disorder, Major with a site in Switzerland are open now. Recruiting first, the newest first:
University of Bern · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University of Bern · Sites in Switzerland
Ages 20–75 · Healthy volunteers
Christoph Nissen · Sites in Switzerland
Ages 30–60 · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18–65
Andreas Walther · Sites in Switzerland
Ages 25–50 · Men only
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 112 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 60 across the 25 interventional studies, 190 across the 5 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
University Hospital, Basel, Switzerland has 2 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
1 of the studies in Depressive Disorder, Major with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059234University of BernThe Motor Activity - Subjective Energy (MASE) Project | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.
Major depressive disorder (MDD) affects nearly 20% of people, but current treatments-both pharmacological and psychotherapeutic-have limited efficacy, especially for mild to severe cases. Psychedelics like LSD, psilocybin, and DMT are being explored as alternative therapies, with studies showing promising antidepressant effects. However, it is unclear whether these benefits stem from their acute subjective (psychedelic) experience or from biological mechanisms like neuroplasticity and anti-inflammatory effects.
This study aims to determine if the antidepressant effects of DMT occur independently of its psychedelic experience. To test this, DMT will be administered under sedation (with propofol) to mask subjective effects, as well as without sedation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DMT without sedation (propofol)
Drug: N,N-Dimethyltryptamine · Procedure: no sedation
DMT with sedation (propofol)
Drug: N,N-Dimethyltryptamine · Procedure: Propofol
Placebo (double-blind) without sedation (propofol)
Drug: Placebo · Procedure: no sedation
Placebo (double-blind) with sedation (propofol)
Drug: Placebo · Procedure: Propofol
administration of a 2mg/min DMT perfusion over 20 min
Also known as: DMT
administration of a placebo perfusion over 20 min
30 min propofol sedation
no sedation
long term changes in depressive symptoms (MADRS)
Changes in depressive symptoms will be assessed using Montgomery-Asberg-Depression Rating Scale (MADRS). The MADRS is a ten-item questionnaire widely used to measure severity of depressive symptoms during the last week. Total score (range 0-60); higher scores indicate greater depression severity.
Time frame: baseline (before intervention) and on day 14 post-intervention
Short term changes in depressive symptoms (MADRS)
Changes in depressive symptoms will be assessed using Montgomery-Asberg-Depression Rating Scale (MADRS). The MADRS is a ten-item questionnaire widely used to measure severity of depressive symptoms during the last week. Total score (range 0-60); higher scores indicate greater depression severity.
Time frame: Baseline (before intervention) and on day 1, 3 and 7 post-intervention
Changes in depressive symptoms (BDI)
Changes in depressive symptoms will be assessed using Beck Depression Inventory (BDI) questionnaire. Total score (range 0-63); higher scores indicate more severe depressive symptoms.
Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention
Changes in anxiety (STAI)
Changes in anxiety will be assessed using the self-reported State-Trait Anxiety Inventory (STAI) questionnaire. Separate total scores for State Anxiety (S-Anxiety) and Trait Anxiety (T-Anxiety) (each range 20-80); higher scores indicate greater anxiety.
Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention
Changes of clinical global impression (CGI-S)
The clinical global impression (CGI) is an instrument for the assessment of the patient's overall functioning both before and after starting the treatment. Severity of Illness (CGI-S): Rated on a 7-point scale (1 = normal, 7 = among the most extremely ill).
Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention
Changes of clinical global impression (CGI-I)
The clinical global impression (CGI) is an instrument for the assessment of the patient's overall functioning both before and after starting the treatment. Improvement (CGI-I): Rated on a 7-point scale (1 = very much improved, 7 = very much worse).
Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention
Changes in quality of life (WHOQOL-bref)
Changes in quality of life will be assessed by World Health Organization Quality of life scale (WHOQOL-bref). The WHOQOL-bref is one of the most commonly used self-rating instruments for the assessment of the quality of life and covers different domains of quality of life (physical, psychological, level of independence, social relationships, and environment, and spirituality). Domain scores (Physical, Psychological, Social, Environmental), scaled from 0 to 100; higher scores indicate better quality of life.
Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention
Persisting positive and negative effects (PEQ)
Psychedelics have been shown to produce persisting effects on well-being and appreciation of social relationships on the PEQ.This questionnaire will be used at the EOS visit to assess similar persisting effects of the DMT experience in addition to any effects on depressive symptomatology. Subscale scores (e.g., positive attitudes, mood changes, spirituality), typically rated 0-5 or 0-6; higher scores indicate stronger persisting effects.
Time frame: On day 14 post-intervention
Acute subjective effects (5D-ASC)
The 5 Dimensions of Altered States of Consciousness (5D-ASC) Scale is a questionnaire containing visual analog scales for 94 items. The instrument contains five scales assessing mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. Each item of the scale is scored on a 0-100 mm VAS. Scores for 5 dimensions (e.g., Oceanic Boundlessness, Anxious Ego Dissolution), range typically 0-100%; higher scores indicate more intense altered states.
Time frame: On day 0 post-intervention
Subjective Effects Rating (SES)
Participants will be asked by the investigator to repeatedly rate their subjective effects verbally on a Likert scale from 0 to 10 for: "any drug effect", "good drug effect", "bad drug effect", and "fear". Ratings will be performed before and repeatedly after substance administration and will take approximately 30 sec to complete. The time course and maximal ratings (Emax, 0-10) are defined for each rating and Emax values compared between treatments using analysis of variance (ANOVAs). Total and subscale scores (range and subscales vary by implementation); higher scores indicate more intense subjective effects.
Time frame: On day 0 pre- and post-intervention
Psychedelic Experience Scale (PES)
In the PES, 100-items are rated on a six-point scale. The PES represents a revalidation of the original 100-item States of Consciousness Questionnaire (SOCQ)
Time frame: On day 0 post-intervention
Emotional breakthrough inventory (EBI)
The Emotional breakthrough inventory (EBI) is a validated instrument with 6 items to assess the degree of emotional breakthrough as a distinct component of the acute psychedelic experience. Total score (range varies); higher scores indicate stronger emotional breakthrough experiences.
Time frame: On day 0 post-intervention
Acute adverse effects
Acute adverse effects wil be assessed by the List of complaints (LC). LC is a self-reporting tool to assess physical and general discomfort. A revised version is used which consists of a 40-item list covering a wide variety of symptoms and complaints that are answered with a four-point intensity-scoring ranging from "not at all" to "strong". Total number or severity of reported somatic and psychological complaints will be evaluated.
Time frame: On day 0 and 1 post-intervention
Safety events
Adverse events will be assessed over the whole study period.
Time frame: From day 0 to day 14 post-intervention
Neuroplasticity
brain-derived neurotrophic factor (BDNF), a biomarker for neurogenesis will be quantified in blood samples collected before and 14 days after intervention
Time frame: Baseline (before intervention) and on day 14 post-intervention
Inflammation
Interleukin-1 beta (IL-1β) an immunological factor linked to depression will be quantified in blood samples collected before and 14 days after intervention
Time frame: Baseline (before intervention) and on day 14 post-intervention
DMT plasma concentration
Plasma levels of DMT will be measured once shortly before the end of the perfusion
Time frame: On day 0 shortly before the end of the perfusion
Expectancy (CEQ)
Expectancy will be assessed before the first drug administration. Thus, patients will know at this timepoint whether they get the treatment with or without propofol. To measure expectancy, a modified 2-item version of the Credibility / Expectancy Questionnaire (CEQ) is used. Credibility score (range 3-27).
Time frame: At Baseline before intervention
Expectancy
The Stanford Expectations of Treatment Scale (SETS) will evaluate positive and negative expectancies. Expectancy score (range 3-27 or expressed as a probability %).
Time frame: At Baseline before intervention
Mood
The Adjective Mood Rating Scale (AMRS) is a self-rating scale assessing current mood states. The AMRS will be used to assess mood before the DMT experience. Positive mood and greater acute well-being is expected to positively enhance the acute DMT effects as similarly shown for other psychedelics. Scores for multiple mood dimensions (e.g., energy, mood, agitation); higher scores reflect greater expression of that dimension.
Time frame: At day 0 directly before administration of the study drug
Personality (NEO-FFI)
Personality traits are known to affect subjective responses to psychoactive substances. The NEO Five Factor Inventory (NEO-FFI) will be used during screening to self-assess personality traits. Scores for five domains (Neuroticism, Extraversion, Openness, Agreeableness, Conscientiousness); raw or standardized T-scores.
Time frame: At Baseline before intervention
Personality (TAS)
Personality traits are known to affect subjective responses to psychoactive substances. The Tellegen Absorption Scale (TAS) will be used during screening to self-assess personality traits. Total score (range 0-34 or 0-136, depending on version); higher scores indicate greater trait absorption.
Time frame: At Baseline before intervention
Sedation Level (RASS)
Level of sedation will be assessed during propofol session after each administration using the validated Richmond Agitation-Sedation Scale (RASS). The RASS is an observer-rated clinical scale used to assess level of agitation and sedation in the intensive care unit. The scale ranges from "+4" (combative) through "0" (alert and calm) to "-5" (unarousable). Intermediate scores include "+3" (very agitation), "+2" (agitated), "+1" (restless), "-1" (drowsy), "-2" (light sedation), "-3" (moderate sedation), and "-4" (deep sedation).
Time frame: On day 0 during intervention
Started Aug 2025 (actual). Primary completion is estimated for Mar 2029, 43 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 43 months is above that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N,N-Dimethyltryptamine
University Hospital, Basel, Switzerland →